treatment with CAZ-AVI — Competitive Intelligence Brief

treatment with CAZ-AVI (treatment with CAZ-AVI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam/beta-lactamase inhibitor combination. Area: Infectious Disease.

marketed Beta-lactam/beta-lactamase inhibitor combination Bacterial penicillin-binding proteins and serine beta-lactamases Infectious Disease Small molecule

Target snapshot

treatment with CAZ-AVI (treatment with CAZ-AVI) — Southeast University, China. CAZ-AVI is a combination of ceftazidime and avibactam that works by inhibiting bacterial beta-lactamases while ceftazidime attacks the bacterial cell wall.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
treatment with CAZ-AVI TARGET	treatment with CAZ-AVI	Southeast University, China	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins and serine beta-lactamases
Piperacillin/Tazobactam Intermittent infusion	Piperacillin/Tazobactam Intermittent infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
CAZ/AVI	CAZ/AVI	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	marketed	Beta-lactam/beta-lactamase inhibitor combination	Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases
Ceftolozane-tazobactam	Ceftolozane-tazobactam	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); bacterial beta-lactamases
Continuos ceftazidime/avibactam infusion	Continuos ceftazidime/avibactam infusion	Ivan Šitum, MD	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); serine beta-lactamases
Piperacillin/Tazobactam Continuous infusion	Piperacillin/Tazobactam Continuous infusion	Ain Shams University	marketed	Beta-lactam/beta-lactamase inhibitor combination	Penicillin-binding proteins (PBPs); beta-lactamases
Ceftazidime-avibactam + Fosfomycin	Ceftazidime-avibactam + Fosfomycin	National University of Singapore	marketed	Beta-lactam/beta-lactamase inhibitor combination + phosphonic acid antibiotic	Penicillin-binding proteins (PBPs), beta-lactamases, MurA enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam/beta-lactamase inhibitor combination class)

1. National University of Singapore · 2 drugs in this class
2. Ain Shams University · 2 drugs in this class
3. Merck Sharp & Dohme LLC · 1 drug in this class
4. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
5. Southeast University, China · 1 drug in this class
6. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
7. Wockhardt · 1 drug in this class
8. Ivan Šitum, MD · 1 drug in this class